20. Literaturverzeichnis – Analkarzinom
1. Balshem, H., Helfand, M., Schunemann, H. J., Oxman, A. D., Kunz, R., Brozek, J., et.al. GRADE guidelines: 3. Rating the quality of evidence, J Clin Epidemiol, 2011. 64(4): p. 401-6., https://www.ncbi.nlm.nih.gov/pubmed/21208779
2. Guyatt, G. H., Oxman, A. D., Vist, G., Kunz, R., Brozek, J., Alonso-Coello, P., et.al. GRADE guidelines: 4. Rating the quality of evidence--study limitations (risk of bias), J Clin Epidemiol, 2011. 64(4): p. 407-15., https://www.ncbi.nlm.nih.gov/pubmed/21247734
3. Guyatt, G. H., Oxman, A. D., Kunz, R., Brozek, J., Alonso-Coello, P., Rind, D., et.al. GRADE guidelines 6. Rating the quality of evidence--imprecision, J Clin Epidemiol, 2011. 64(12): p. 1283-93., https://www.ncbi.nlm.nih.gov/pubmed/21839614
4. Guyatt, G. H., Oxman, A. D., Kunz, R., Woodcock, J., Brozek, J., Helfand, M., et.al. GRADE guidelines: 7. Rating the quality of evidence--inconsistency, J Clin Epidemiol, 2011. 64(12): p. 1294-302., https://www.ncbi.nlm.nih.gov/pubmed/21803546
5. Guyatt, G. H., Oxman, A. D., Kunz, R., Woodcock, J., Brozek, J., Helfand, M., et.al. GRADE guidelines: 8. Rating the quality of evidence--indirectness, J Clin Epidemiol, 2011. 64(12): p. 1303-10., https://www.ncbi.nlm.nih.gov/pubmed/21802903
6. Guyatt, G. H., Oxman, A. D., Montori, V., Vist, G., Kunz, R., Brozek, J., et.al. GRADE guidelines: 5. Rating the quality of evidence--publication bias, J Clin Epidemiol, 2011. 64(12): p. 1277-82., https://www.ncbi.nlm.nih.gov/pubmed/21802904
7. Meerpohl, J. J., Langer, G., Perleth, M., Gartlehner, G., Kaminski-Hartenthaler, A., Schunemann, H., [GRADE guidelines: 3. Rating the quality of evidence (confidence in the estimates of effect)], Z Evid Fortbild Qual Gesundhwes, 2012. 106(6): p. 449-56., https://www.ncbi.nlm.nih.gov/pubmed/22857733
8. Andrews, J., Guyatt, G., Oxman, A. D., Alderson, P., Dahm, P., Falck-Ytter, Y., et.al. GRADE guidelines: 14. Going from evidence to recommendations: the significance and presentation of recommendations, J Clin Epidemiol, 2013. 66(7): p. 719-25., https://www.ncbi.nlm.nih.gov/pubmed/23312392
9. Kaminski-Hartenthaler, A., Meerpohl, J. J., Gartlehner, G., Kien, C., Langer, G., Wipplinger, J., et.al. [GRADE guidelines: 14. Going from evidence to recommendations: the significance and presentation of recommendations], Z Evid Fortbild Qual Gesundhwes, 2014. 108(7): p. 413-20., https://www.ncbi.nlm.nih.gov/pubmed/25444300
10. AWMF - Association of Scientific Medical Societies, Das AWMF-Regelwerk Leitlinien, 2012., https://www.awmf.org/regelwerk/
11. Andrews, J. C., Schunemann, H. J., Oxman, A. D., Pottie, K., Meerpohl, J. J., Coello, P. A., et.al. GRADE guidelines: 15. Going from evidence to recommendation-determinants of a recommendation's direction and strength, J Clin Epidemiol, 2013. 66(7): p. 726-35., https://www.ncbi.nlm.nih.gov/pubmed/23570745
12. Alonso-Coello, P., Oxman, A. D., Moberg, J., Brignardello-Petersen, R., Akl, E. A., Davoli, M., et.al. GRADE Evidence to Decision (EtD) frameworks: a systematic and transparent approach to making well informed healthcare choices. 2: Clinical practice guidelines, BMJ, 2016. 353: p. i2089., https://www.ncbi.nlm.nih.gov/pubmed/27365494
13. Alonso-Coello, P., Schunemann, H. J., Moberg, J., Brignardello-Petersen, R., Akl, E. A., Davoli, M., et.al. GRADE Evidence to Decision (EtD) frameworks: a systematic and transparent approach to making well informed healthcare choices. 1: Introduction, BMJ, 2016. 353: p. i2016., https://www.ncbi.nlm.nih.gov/pubmed/27353417
14. Benson, A. B., 3rd, Arnoletti, J. P., Bekaii-Saab, T., Chan, E., Chen, Y. J., Choti, M. A., et.al. Anal Carcinoma, Version 2.2012: featured updates to the NCCN guidelines, J Natl Compr Canc Netw, 2012. 10(4): p. 449-54., https://www.ncbi.nlm.nih.gov/pubmed/22491045
15. Geh, I., Gollins, S., Renehan, A., Scholefield, J., Goh, V., Prezzi, D., et.al. Association of Coloproctology of Great Britain & Ireland (ACPGBI): Guidelines for the Management of Cancer of the Colon, Rectum and Anus (2017) - Anal Cancer, Colorectal Dis, 2017. 19 Suppl 1: p. 82-97., https://www.ncbi.nlm.nih.gov/pubmed/28632308
16. Glynne-Jones, R., Nilsson, P. J., Aschele, C., Goh, V., Peiffert, D., Cervantes, A., et.al. Anal cancer: ESMO-ESSO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Ann Oncol, 2014. 25 Suppl 3: p. iii10-20., https://www.ncbi.nlm.nih.gov/pubmed/25001200
17. Moureau-Zabotto, L., Vendrely, V., Abramowitz, L., Borg, C., Francois, E., Goere, D., et.al. Anal cancer: French Intergroup Clinical Practice Guidelines for diagnosis, treatment and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, SNFCP), Dig Liver Dis, 2017. 49(8): p. 831-840., https://www.ncbi.nlm.nih.gov/pubmed/28610905
18. Lin, C., Franceschi, S., Clifford, G. M., Human papillomavirus types from infection to cancer in the anus, according to sex and HIV status: a systematic review and meta-analysis, Lancet Infect Dis, 2018. 18(2): p. 198-206., https://www.ncbi.nlm.nih.gov/pubmed/29158102
19. Rodel, F., Wieland, U., Fraunholz, I., Kitz, J., Rave-Frank, M., Wolff, H. A., et.al. Human papillomavirus DNA load and p16INK4a expression predict for local control in patients with anal squamous cell carcinoma treated with chemoradiotherapy, Int J Cancer, 2015. 136(2): p. 278-88., https://www.ncbi.nlm.nih.gov/pubmed/24839133
20. McBride, A. A., Warburton, A., The role of integration in oncogenic progression of HPV-associated cancers, PLoS Pathog, 2017. 13(4): p. e1006211., https://www.ncbi.nlm.nih.gov/pubmed/28384274
21. Bernardi, M. P., Ngan, S. Y., Michael, M., Lynch, A. C., Heriot, A. G., Ramsay, R. G., et.al. Molecular biology of anal squamous cell carcinoma: implications for future research and clinical intervention, Lancet Oncol, 2015. 16(16): p. e611-21., https://www.ncbi.nlm.nih.gov/pubmed/26678214
22. Berry, J. M., Jay, N., Cranston, R. D., Darragh, T. M., Holly, E. A., Welton, M. L., et.al. Progression of anal high-grade squamous intraepithelial lesions to invasive anal cancer among HIV-infected men who have sex with men, Int J Cancer, 2014. 134(5): p. 1147-55., https://www.ncbi.nlm.nih.gov/pubmed/23934991
23. Gosens, K. C., Richel, O., Prins, J. M., Human papillomavirus as a cause of anal cancer and the role of screening, Curr Opin Infect Dis, 2017. 30(1): p. 87-92., https://www.ncbi.nlm.nih.gov/pubmed/27845952
24. Machalek, D. A., Poynten, M., Jin, F., Fairley, C. K., Farnsworth, A., Garland, S. M., et.al. Anal human papillomavirus infection and associated neoplastic lesions in men who have sex with men: a systematic review and meta-analysis, Lancet Oncol, 2012. 13(5): p. 487-500., https://www.ncbi.nlm.nih.gov/pubmed/22445259
25. Amirian, E. S., Fickey, P. A., Jr., Scheurer, M. E., Chiao, E. Y., Anal cancer incidence and survival: comparing the greater San-Francisco bay area to other SEER cancer registries, PLoS One, 2013. 8(3): p. e58919., https://www.ncbi.nlm.nih.gov/pubmed/23484057
26. Arens, Y., Gaisa, M., Goldstone, S. E., Liu, Y., Wisnivesky, J., Sigel, C. S., et.al. Risk of Invasive Anal Cancer in HIV-Infected Patients With High-Grade Anal Dysplasia: A Population-Based Cohort Study, Dis Colon Rectum, 2019. 62(8): p. 934-940., https://www.ncbi.nlm.nih.gov/pubmed/30888979
27. Mathews, W. C., Agmas, W., Cachay, E. R., Cosman, B. C., Jackson, C., Natural history of anal dysplasia in an HIV-infected clinical care cohort: estimates using multi-state Markov modeling, PLoS One, 2014. 9(8): p. e104116., https://www.ncbi.nlm.nih.gov/pubmed/25101757
28. Cachay, E., Agmas, W., Mathews, C., Five-year cumulative incidence of invasive anal cancer among HIV-infected patients according to baseline anal cytology results: an inception cohort analysis, HIV Med, 2015. 16(3): p. 191-5., https://www.ncbi.nlm.nih.gov/pubmed/25197003
29. Tong, W. W., Shepherd, K., Garland, S., Meagher, A., Templeton, D. J., Fairley, C. K., et.al. Human papillomavirus 16-specific T-cell responses and spontaneous regression of anal high-grade squamous intraepithelial lesions, J Infect Dis, 2015. 211(3): p. 405-15., https://www.ncbi.nlm.nih.gov/pubmed/25139018
30. Robert Koch Institut, Zentrum für Krebsregisterdaten - DatenbankabfrageRobert Koch Institut,,, 2019., https://www.krebsdaten.de/Krebs/SiteGlobals/Forms/Datenbankabfrage/datenbankabfrage_stufe2_form.html
31. Jiang, Y., Ajani, J. A., Anal margin cancer: current situation and ongoing trials, Curr Opin Oncol, 2012. 24(4): p. 448-53., https://www.ncbi.nlm.nih.gov/pubmed/22581355
32. Valvo, F., Ciurlia, E., Avuzzi, B., Doci, R., Ducreux, M., Roelofsen, F., et.al. Cancer of the anal region, Crit Rev Oncol Hematol, 2019. 135: p. 115-127., https://www.ncbi.nlm.nih.gov/pubmed/30819440
33. Gatta, G., Capocaccia, R., Botta, L., Mallone, S., De Angelis, R., Ardanaz, E., et.al. Burden and centralised treatment in Europe of rare tumours: results of RARECAREnet-a population-based study, Lancet Oncol, 2017. 18(8): p. 1022-1039., https://www.ncbi.nlm.nih.gov/pubmed/28687376
34. Van Dyne, E. A., Henley, S. J., Saraiya, M., Thomas, C. C., Markowitz, L. E., Benard, V. B., Trends in Human Papillomavirus-Associated Cancers - United States, 1999-2015, MMWR Morb Mortal Wkly Rep, 2018. 67(33): p. 918-924., https://www.ncbi.nlm.nih.gov/pubmed/30138307
35. Nielsen, A., Munk, C., Kjaer, S. K., Trends in incidence of anal cancer and high-grade anal intraepithelial neoplasia in Denmark, 1978-2008, Int J Cancer, 2012. 130(5): p. 1168-73., https://www.ncbi.nlm.nih.gov/pubmed/21469144
36. Wilkinson, J. R., Morris, E. J., Downing, A., Finan, P. J., Aravani, A., Thomas, J. D., et.al. The rising incidence of anal cancer in England 1990-2010: a population-based study, Colorectal Dis, 2014. 16(7): p. O234-9., https://www.ncbi.nlm.nih.gov/pubmed/24410872
37. Daling, J. R., Madeleine, M. M., Johnson, L. G., Schwartz, S. M., Shera, K. A., Wurscher, M. A., et.al. Human papillomavirus, smoking, and sexual practices in the etiology of anal cancer, Cancer, 2004. 101(2): p. 270-80., https://www.ncbi.nlm.nih.gov/pubmed/15241823
38. Daling, J. R., Weiss, N. S., Hislop, T. G., Maden, C., Coates, R. J., Sherman, K. J., et.al. Sexual practices, sexually transmitted diseases, and the incidence of anal cancer, N Engl J Med, 1987. 317(16): p. 973-7., https://www.ncbi.nlm.nih.gov/pubmed/2821396
39. Holly, E. A., Whittemore, A. S., Aston, D. A., Ahn, D. K., Nickoloff, B. J., Kristiansen, J. J., Anal cancer incidence: genital warts, anal fissure or fistula, hemorrhoids, and smoking, J Natl Cancer Inst, 1989. 81(22): p. 1726-31., https://www.ncbi.nlm.nih.gov/pubmed/2810388
40. Silverberg, M. J., Lau, B., Justice, A. C., Engels, E., Gill, M. J., Goedert, J. J., et.al. Risk of anal cancer in HIV-infected and HIV-uninfected individuals in North America, Clin Infect Dis, 2012. 54(7): p. 1026-34., https://www.ncbi.nlm.nih.gov/pubmed/22291097
41. Chaturvedi, A. K., Engels, E. A., Gilbert, E. S., Chen, B. E., Storm, H., Lynch, C. F., et.al. Second cancers among 104,760 survivors of cervical cancer: evaluation of long-term risk, J Natl Cancer Inst, 2007. 99(21): p. 1634-43., https://www.ncbi.nlm.nih.gov/pubmed/17971527
42. Hemminki, K., Dong, C., Vaittinen, P., Second primary cancer after in situ and invasive cervical cancer, Epidemiology, 2000. 11(4): p. 457-61., https://www.ncbi.nlm.nih.gov/pubmed/10874555
43. Lin, C., Slama, J., Gonzalez, P., Goodman, M. T., Xia, N., Kreimer, A. R., et.al. Cervical determinants of anal HPV infection and high-grade anal lesions in women: a collaborative pooled analysis, Lancet Infect Dis, 2019. 19(8): p. 880-891., https://www.ncbi.nlm.nih.gov/pubmed/31204304
44. Saleem, A. M., Paulus, J. K., Shapter, A. P., Baxter, N. N., Roberts, P. L., Ricciardi, R., Risk of anal cancer in a cohort with human papillomavirus-related gynecologic neoplasm, Obstet Gynecol, 2011. 117(3): p. 643-9., https://www.ncbi.nlm.nih.gov/pubmed/21343768
45. Sunesen, K. G., Norgaard, M., Thorlacius-Ussing, O., Laurberg, S., Immunosuppressive disorders and risk of anal squamous cell carcinoma: a nationwide cohort study in Denmark, 1978-2005, Int J Cancer, 2010. 127(3): p. 675-84., https://www.ncbi.nlm.nih.gov/pubmed/19960431
46. Meeuwis, K. A., Melchers, W. J., Bouten, H., van de Kerkhof, P. C., Hinten, F., Quint, W. G., et.al. Anogenital malignancies in women after renal transplantation over 40 years in a single center, Transplantation, 2012. 93(9): p. 914-22., https://www.ncbi.nlm.nih.gov/pubmed/22377788
47. Alloub, M. I., Barr, B. B., McLaren, K. M., Smith, I. W., Bunney, M. H., Smart, G. E., Human papillomavirus infection and cervical intraepithelial neoplasia in women with renal allografts, BMJ, 1989. 298(6667): p. 153-6., https://www.ncbi.nlm.nih.gov/pubmed/2538174
48. Grulich, A. E., van Leeuwen, M. T., Falster, M. O., Vajdic, C. M., Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis, Lancet, 2007. 370(9581): p. 59-67., https://www.ncbi.nlm.nih.gov/pubmed/17617273
49. Ogunbiyi, O. A., Scholefield, J. H., Raftery, A. T., Smith, J. H., Duffy, S., Sharp, F., et.al. Prevalence of anal human papillomavirus infection and intraepithelial neoplasia in renal allograft recipients, Br J Surg, 1994. 81(3): p. 365-7., https://www.ncbi.nlm.nih.gov/pubmed/8173899
50. Patel, H. S., Silver, A. R., Levine, T., Williams, G., Northover, J. M., Human papillomavirus infection and anal dysplasia in renal transplant recipients, Br J Surg, 2010. 97(11): p. 1716-21., https://www.ncbi.nlm.nih.gov/pubmed/20730855
51. Madeleine, M. M., Finch, J. L., Lynch, C. F., Goodman, M. T., Engels, E. A., HPV-related cancers after solid organ transplantation in the United States, Am J Transplant, 2013. 13(12): p. 3202-9., https://www.ncbi.nlm.nih.gov/pubmed/24119294
52. Aigner, F., Boeckle, E., Albright, J., Kilo, J., Boesmueller, C., Conrad, F., et.al. Malignancies of the colorectum and anus in solid organ recipients, Transpl Int, 2007. 20(6): p. 497-504., https://www.ncbi.nlm.nih.gov/pubmed/17343685
53. Daling, J. R., Sherman, K. J., Hislop, T. G., Maden, C., Mandelson, M. T., Beckmann, A. M., et.al. Cigarette smoking and the risk of anogenital cancer, Am J Epidemiol, 1992. 135(2): p. 180-9., https://www.ncbi.nlm.nih.gov/pubmed/1311142
54. Nordenvall, C., Nilsson, P. J., Ye, W., Nyren, O., Smoking, snus use and risk of right- and left-sided colon, rectal and anal cancer: a 37-year follow-up study, Int J Cancer, 2011. 128(1): p. 157-65., https://www.ncbi.nlm.nih.gov/pubmed/20209500
55. Phillips, D. H., Hewer, A., Scholefield, J. H., Skinner, P., Smoking-related DNA adducts in anal epithelium, Mutat Res, 2004. 560(2): p. 167-72., https://www.ncbi.nlm.nih.gov/pubmed/15157654
56. Beaugerie, L., Carrat, F., Nahon, S., Zeitoun, J. D., Sabate, J. M., Peyrin-Biroulet, L., et.al. High Risk of Anal and Rectal Cancer in Patients With Anal and/or Perianal Crohn's Disease, Clin Gastroenterol Hepatol, 2018. 16(6): p. 892-899 e2., https://www.ncbi.nlm.nih.gov/pubmed/29199142
57. AWMF - Association of Scientific Medical Societies, HPV-assoziierte Läsionen der äußeren Genitoanalregion und des Anus – Genitalwarzen und Krebsvorstufen der Vulva, des Penis und der peri- und intraanalen Haut S2k-LL (PEG), 2017., http://www.awmf.org/leitlinien/detail/ll/082-008.html
58. Gross, G. E., Werner, R. N., Becker, J. C., Brockmeyer, N. H., Esser, S., Hampl, M., et.al. S2k-Leitlinie: HPV-assoziierte Lasionen der ausseren Genitalregion und des Anus - Genitalwarzen und Krebsvorstufen der Vulva, des Penis und der peri- und intraanalen Haut (Kurzfassung), J Dtsch Dermatol Ges, 2018. 16(2): p. 242-256., https://www.ncbi.nlm.nih.gov/pubmed/29418090
59. AWMF - Association of Scientific Medical Societies, Anale Dysplasien und Analkarzinom bei HIV-Infizierten: Prävention, Diagnostik und Therapie. S2k-LL (DAIG), 2013., http://www.awmf.org/leitlinien/detail/ll/055-007.html
60. Esser, S., Kreuter, A., Oette, M., Gingelmaier, A., Mosthaf, F., Sautter-Bihl, M. L., et.al. German-Austrian guidelines on anal dysplasia and anal cancer in HIV-positive individuals: prevention, diagnosis, and treatment, J Dtsch Dermatol Ges, 2015. 13(12): p. 1302-19., https://www.ncbi.nlm.nih.gov/pubmed/26612810
61. AJCC Cancer Staging ManualSpringer International Publishing, 2017.
62. AHRQ - Agency for Healthcare Research + Quality, ACR Appropriateness Criteria® anal cancer. American College of Radiology. NGC:010175, 2013., http://www.guideline.gov/content.aspx?id=47690
63. Fenger, C., Frisch, M., Marti, M. C., Parc, R., Tumours of the anal canalIARC Press, World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of the Digestive System, 2000.
64. Grabenbauer, G. G., Kessler, H., Matzel, K. E., Sauer, R., Hohenberger, W., Schneider, I. H., Tumor site predicts outcome after radiochemotherapy in squamous-cell carcinoma of the anal region: long-term results of 101 patients, Dis Colon Rectum, 2005. 48(9): p. 1742-51., https://www.ncbi.nlm.nih.gov/pubmed/15991058
65. Wieghard, N., Hart, K. D., Kelley, K., Lu, K. C., Herzig, D. O., Mitin, T., et.al. HIV positivity and anal cancer outcomes: A single-center experience, Am J Surg, 2016. 211(5): p. 886-93., https://www.ncbi.nlm.nih.gov/pubmed/26988618
66. Gunderson, L. L., Moughan, J., Ajani, J. A., Pedersen, J. E., Winter, K. A., Benson, A. B., 3rd, et.al. Anal carcinoma: impact of TN category of disease on survival, disease relapse, and colostomy failure in US Gastrointestinal Intergroup RTOG 98-11 phase 3 trial, Int J Radiat Oncol Biol Phys, 2013. 87(4): p. 638-45., https://www.ncbi.nlm.nih.gov/pubmed/24035327
67. Goffredo, P., Garancini, M., Robinson, T. J., Frakes, J., Hoshi, H., Hassan, I., A National-Level Validation of the New American Joint Committee on Cancer 8th Edition Subclassification of Stage IIA and B Anal Squamous Cell Cancer, Ann Surg Oncol, 2018. 25(6): p. 1654-1660., https://www.ncbi.nlm.nih.gov/pubmed/29572706
68. Correa, J. H., Castro, L. S., Kesley, R., Dias, J. A., Jesus, J. P., Olivatto, L. O., et.al. Salvage abdominoperineal resection for anal cancer following chemoradiation: a proposed scoring system for predicting postoperative survival, J Surg Oncol, 2013. 107(5): p. 486-92., https://www.ncbi.nlm.nih.gov/pubmed/23129564
69. Faivre, J. C., Peiffert, D., Vendrely, V., Lemanski, C., Hannoun-Levi, J. M., Mirabel, X., et.al. Prognostic factors of colostomy free survival in patients presenting with locally advanced anal canal carcinoma: A pooled analysis of two prospective trials (KANAL 2 and ACCORD 03), Radiother Oncol, 2018. 129(3): p. 463-470., https://www.ncbi.nlm.nih.gov/pubmed/30172453
70. Kapacee, Z. A., Susnerwala, S., Wise, M., Biswas, A., Danwata, F., Scott, N., Chemoradiotherapy for squamous cell anal carcinoma: a review of prognostic factors, Colorectal Dis, 2016. 18(11): p. 1080-1086., https://www.ncbi.nlm.nih.gov/pubmed/27028038
71. Glynne-Jones, R., Sebag-Montefiore, D., Adams, R., Gollins, S., Harrison, M., Meadows, H. M., et.al. Prognostic factors for recurrence and survival in anal cancer: generating hypotheses from the mature outcomes of the first United Kingdom Coordinating Committee on Cancer Research Anal Cancer Trial (ACT I), Cancer, 2013. 119(4): p. 748-55., https://www.ncbi.nlm.nih.gov/pubmed/23011911
72. Ajani, J. A., Winter, K. A., Gunderson, L. L., Pedersen, J., Benson, A. B., 3rd, Thomas, C. R., Jr., et.al. Prognostic factors derived from a prospective database dictate clinical biology of anal cancer: the intergroup trial (RTOG 98-11), Cancer, 2010. 116(17): p. 4007-13., https://www.ncbi.nlm.nih.gov/pubmed/20564111
73. Bartelink, H., Roelofsen, F., Eschwege, F., Rougier, P., Bosset, J. F., Gonzalez, D. G., et.al. Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a phase III randomized trial of the European Organization for Research and Treatment of Cancer Radiotherapy and Gastrointestinal Cooperative Groups, J Clin Oncol, 1997. 15(5): p. 2040-9., https://www.ncbi.nlm.nih.gov/pubmed/9164216
74. Crum-Cianflone, N. F., Hullsiek, K. H., Marconi, V. C., Ganesan, A., Weintrob, A., Barthel, R. V., et.al. Anal cancers among HIV-infected persons: HAART is not slowing rising incidence, AIDS, 2010. 24(4): p. 535-43., https://www.ncbi.nlm.nih.gov/pubmed/19926961
75. Pappou, E. P., Magruder, J. T., Fu, T., Hicks, C. W., Herman, J. M., Fang, S., et.al. Prognostic and Predictive Clinicopathologic Factors of Squamous Anal Canal Cancer in HIV-Positive and HIV-Negative Patients: Does HAART Influence Outcomes?, World J Surg, 2018. 42(3): p. 876-883., https://www.ncbi.nlm.nih.gov/pubmed/28948325
76. Marcus, J. L., Chao, C., Leyden, W. A., Xu, L., Yu, J., Horberg, M. A., et.al. Survival among HIV-infected and HIV-uninfected individuals with common non-AIDS-defining cancers, Cancer Epidemiol Biomarkers Prev, 2015. 24(8): p. 1167-73., https://www.ncbi.nlm.nih.gov/pubmed/25713023
77. Coghill, A. E., Shiels, M. S., Suneja, G., Engels, E. A., Elevated Cancer-Specific Mortality Among HIV-Infected Patients in the United States, J Clin Oncol, 2015. 33(21): p. 2376-83., https://www.ncbi.nlm.nih.gov/pubmed/26077242
78. Palefsky, J. M., Giuliano, A. R., Goldstone, S., Moreira, E. D., Jr., Aranda, C., Jessen, H., et.al. HPV vaccine against anal HPV infection and anal intraepithelial neoplasia, N Engl J Med, 2011. 365(17): p. 1576-85., https://www.ncbi.nlm.nih.gov/pubmed/22029979
79. Robert Koch-Institut (RKI), Empfehlungen der Ständigen Impfkommission beim Robert Koch-Institut – 2019/2020, Epidemiologisches Bulletin 34/2019, 2019., https://www.rki.de/DE/Aktuelles/Publikationen/Epidemiologisches-Bulletin/2019/34_19.pdf?__blob=publicationFile&v=3
80. AWMF - Association of Scientific Medical Societies, Angemeldetes Leitlinienvorhaben: Impfprävention HPV-assoziierter Neoplasien, 2018., https://www.awmf.org/leitlinien/detail/anmeldung/1/ll/082-002.html
81. European AIDS Clinical Society, EACS Guidelines, Version 10.0, November 2019, 2019., https://www.eacsociety.org/files/2019_guidelines-10.0_final.pdf
82. Silverberg, M. J., Lau, B., Achenbach, C. J., Jing, Y., Althoff, K. N., D'Souza, G., et.al. Cumulative Incidence of Cancer Among Persons With HIV in North America: A Cohort Study, Ann Intern Med, 2015. 163(7): p. 507-18., https://www.ncbi.nlm.nih.gov/pubmed/26436616
83. Richel, O., Van Der Zee, R. P., Smit, C., De Vries, H. J., Prins, J. M., Brief Report: Anal Cancer in the HIV-Positive Population: Slowly Declining Incidence After a Decade of cART, J Acquir Immune Defic Syndr, 2015. 69(5): p. 602-5., https://www.ncbi.nlm.nih.gov/pubmed/26167621
84. PDQ Screening and Prevention Editorial Board, Anal Cancer Prevention (PDQ®) - Health Professional Version, 2019., https://www.ncbi.nlm.nih.gov/books/NBK179253/
85. Revollo, B., Videla, S., Llibre, J. M., Paredes, R., Pinol, M., Garcia-Cuyas, F., et.al. Routine screening of anal cytology in HIV-infected subjects and the impact on invasive anal cancer. A prospective cohort study, Clin Infect Dis, 2019., https://www.ncbi.nlm.nih.gov/pubmed/31504329
86. NEW YORK STATE DEPARTMENT OF HEALTH AIDS INSTITUTE, Anal Dysplasia and Cancer Guideline, 2007., https://www.hivguidelines.org/guideline/hiv-anal-cancer/
87. Ontario Medical Advisory Secretariat, Anal dysplasia screening: evidence-based analysisTitle to be Checked, Ontario Health Technology Assessment Series, 2007. 7(4): p. 45.
88. Giani, I., Mistrangelo, M., Fucini, C., Italian Society of Colo-Rectal, Surgery, The treatment of squamous anal carcinoma: guidelines of the Italian Society of Colo-Rectal Surgery, Tech Coloproctol, 2013. 17(2): p. 171-9., https://www.ncbi.nlm.nih.gov/pubmed/23143219
89. Wells, J. S., Holstad, M. M., Thomas, T., Bruner, D. W., An integrative review of guidelines for anal cancer screening in HIV-infected persons, AIDS Patient Care STDS, 2014. 28(7): p. 350-7., https://www.ncbi.nlm.nih.gov/pubmed/24936878
90. Leeds, I. L., Fang, S. H., Anal cancer and intraepithelial neoplasia screening: A review, World J Gastrointest Surg, 2016. 8(1): p. 41-51., https://www.ncbi.nlm.nih.gov/pubmed/26843912
91. Stewart, D. B., Gaertner, W. B., Glasgow, S. C., Herzig, D. O., Feingold, D., Steele, S. R., et.al. The American Society of Colon and Rectal Surgeons Clinical Practice Guidelines for Anal Squamous Cell Cancers (Revised 2018), Dis Colon Rectum, 2018. 61(7): p. 755-774., https://www.ncbi.nlm.nih.gov/pubmed/29878949
92. Moscicki, A. B., Darragh, T. M., Berry-Lawhorn, J. M., Roberts, J. M., Khan, M. J., Boardman, L. A., et.al. Screening for Anal Cancer in Women, J Low Genit Tract Dis, 2015. 19(3 Suppl 1): p. S27-42., https://www.ncbi.nlm.nih.gov/pubmed/26103446
93. Brickman, C., Palefsky, J. M., Human papillomavirus in the HIV-infected host: epidemiology and pathogenesis in the antiretroviral era, Curr HIV/AIDS Rep, 2015. 12(1): p. 6-15., https://www.ncbi.nlm.nih.gov/pubmed/25644977
94. Morton, M., Melnitchouk, N., Bleday, R., Squamous cell carcinoma of the anal canal, Curr Probl Cancer, 2018. 42(5): p. 486-492., https://www.ncbi.nlm.nih.gov/pubmed/30497849
95. Roberts, J. R., Siekas, L. L., Kaz, A. M., Anal intraepithelial neoplasia: A review of diagnosis and management, World J Gastrointest Oncol, 2017. 9(2): p. 50-61., https://www.ncbi.nlm.nih.gov/pubmed/28255426
96. Societies, Awmf Association of Scientific Medical, Anale Dysplasien und Analkarzinom bei HIV-Infizierten: Prävention, Diagnostik und Therapie. S2k-LL (DAIG), 2013., http://www.awmf.org/leitlinien/detail/ll/055-007.html
97. Oette, M., Wieland, U., Schunemann, M., Haes, J., Reuter, S., Jensen, B. E., et.al. Anal chromoendoscopy using gastroenterological video-endoscopes: A new method to perform high resolution anoscopy for diagnosing intraepithelial neoplasia and anal carcinoma in HIV-infected patients, Z Gastroenterol, 2017. 55(1): p. 23-31., https://www.ncbi.nlm.nih.gov/pubmed/27806411
98. Goldie, S. J., Kuntz, K. M., Weinstein, M. C., Freedberg, K. A., Welton, M. L., Palefsky, J. M., The clinical effectiveness and cost-effectiveness of screening for anal squamous intraepithelial lesions in homosexual and bisexual HIV-positive men, JAMA, 1999. 281(19): p. 1822-9., https://www.ncbi.nlm.nih.gov/pubmed/10340370
99. Silling, S., Kreuter, A., Hellmich, M., Swoboda, J., Pfister, H., Wieland, U., Human papillomavirus oncogene mRNA testing for the detection of anal dysplasia in HIV-positive men who have sex with men, J Clin Virol, 2012. 53(4): p. 325-31., https://www.ncbi.nlm.nih.gov/pubmed/22261122
100. Hillman, R. J., Berry-Lawhorn, J. M., Ong, J. J., Cuming, T., Nathan, M., Goldstone, S., et.al. International Anal Neoplasia Society Guidelines for the Practice of Digital Anal Rectal Examination, J Low Genit Tract Dis, 2019. 23(2): p. 138-146., https://www.ncbi.nlm.nih.gov/pubmed/30907777
101. Ong, J. J., Chen, M., Grulich, A. E., Fairley, C. K., Regional and national guideline recommendations for digital ano-rectal examination as a means for anal cancer screening in HIV positive men who have sex with men: a systematic review, BMC Cancer, 2014. 14: p. 557., https://www.ncbi.nlm.nih.gov/pubmed/25081485
102. Kreuter, A., Siorokos, C., Oellig, F., Silling, S., Pfister, H., Wieland, U., High-grade Dysplasia in Anogenital Warts of HIV-Positive Men, JAMA Dermatol, 2016. 152(11): p. 1225-1230., https://www.ncbi.nlm.nih.gov/pubmed/27463201
103. Schlecht, H. P., Fugelso, D. K., Murphy, R. K., Wagner, K. T., Doweiko, J. P., Proper, J., et.al. Frequency of occult high-grade squamous intraepithelial neoplasia and invasive cancer within anal condylomata in men who have sex with men, Clin Infect Dis, 2010. 51(1): p. 107-10., https://www.ncbi.nlm.nih.gov/pubmed/20482370
104. Glynne-Jones, R., Sebag-Montefiore, D., Meadows, H. M., Cunningham, D., Begum, R., Adab, F., et.al. Best time to assess complete clinical response after chemoradiotherapy in squamous cell carcinoma of the anus (ACT II): a post-hoc analysis of randomised controlled phase 3 trial, Lancet Oncol, 2017. 18(3): p. 347-356., https://www.ncbi.nlm.nih.gov/pubmed/28209296
105. AWMF - Association of Scientific Medical Societies, Diagnostik und Therapie des Analekzems, AWMF-Register-Nr.: 013/007, 2019., https://www.awmf.org/uploads/tx_szleitlinien/013-007l_S1_Anakekzem-Diagnostik-Therapie_2019-10_1.pdf
106. Scholefield, J. H., Harris, D., Radcliffe, A., Guidelines for management of anal intraepithelial neoplasia, Colorectal Dis, 2011. 13 Suppl 1: p. 3-10., https://www.ncbi.nlm.nih.gov/pubmed/21251167
107. Chai, C. Y., Tran Cao, H. S., Awad, S., Massarweh, N. N., Management of Stage I Squamous Cell Carcinoma of the Anal Canal, JAMA Surg, 2018. 153(3): p. 209-215., https://www.ncbi.nlm.nih.gov/pubmed/29049547
108. Deshmukh, A. A., Zhao, H., Das, P., Chiao, E. Y., You, Y. N., Franzini, L., et.al. Clinical and Economic Evaluation of Treatment Strategies for T1N0 Anal Canal Cancer, Am J Clin Oncol, 2018. 41(7): p. 626-631., https://www.ncbi.nlm.nih.gov/pubmed/27755059
109. Kynaston, J. W. F., Maccabe, T., Parwaiz, I., Cullen, W., Longman, R. J., Messenger, D., et.al. Management of early anal squamous cell cancer: Observational cohort study, Colorectal Disease, 2018. 20 (Supplement 4): p. 105., https://doi.org/10.1111/codi.14329
110. Hocquelet, A., Auriac, T., Perier, C., Dromain, C., Meyer, M., Pinaquy, J. B., et.al. Pre-treatment magnetic resonance-based texture features as potential imaging biomarkers for predicting event free survival in anal cancer treated by chemoradiotherapy, Eur Radiol, 2018. 28(7): p. 2801-2811., https://www.ncbi.nlm.nih.gov/pubmed/29404766
111. Otto, S. D., Lee, L., Buhr, H. J., Frericks, B., Hocht, S., Kroesen, A. J., Staging anal cancer: prospective comparison of transanal endoscopic ultrasound and magnetic resonance imaging, J Gastrointest Surg, 2009. 13(7): p. 1292-8., https://www.ncbi.nlm.nih.gov/pubmed/19365694
112. Reginelli, A., Granata, V., Fusco, R., Granata, F., Rega, D., Roberto, L., et.al. Diagnostic performance of magnetic resonance imaging and 3D endoanal ultrasound in detection, staging and assessment post treatment, in anal cancer, Oncotarget, 2017. 8(14): p. 22980-22990., https://www.ncbi.nlm.nih.gov/pubmed/28152518
113. Mahmud, A., Poon, R., Jonker, D., PET imaging in anal canal cancer: a systematic review and meta-analysis, Br J Radiol, 2017. 90(1080): p. 20170370., https://www.ncbi.nlm.nih.gov/pubmed/28972796
114. Sekhar, H., Zwahlen, M., Trelle, S., Malcomson, L., Kochhar, R., Saunders, M. P., et.al. Nodal stage migration and prognosis in anal cancer: a systematic review, meta-regression, and simulation study, Lancet Oncol, 2017. 18(10): p. 1348-1359., https://www.ncbi.nlm.nih.gov/pubmed/28802802
115. Wade, D. S., Herrera, L., Castillo, N. B., Petrelli, N. J., Metastases to the lymph nodes in epidermoid carcinoma of the anal canal studied by a clearing technique, Surg Gynecol Obstet, 1989. 169(3): p. 238-42., https://www.ncbi.nlm.nih.gov/pubmed/2672386
116. Bhuva, N., Harrison, M., To Pet or Not to Pet? That Is the Question. Staging in Anal Cancer, Annals of Oncology, 2011. 22: p. v126-v127., https://pubmed.ncbi.nlm.nih.gov/22294527/
117. Caldarella, C., Annunziata, S., Treglia, G., Sadeghi, R., Ayati, N., Giovanella, L., Diagnostic performance of positron emission tomography/computed tomography using fluorine-18 fluorodeoxyglucose in detecting locoregional nodal involvement in patients with anal canal cancer: a systematic review and meta-analysis (Provisional abstract), Scientific World Journal, 2014. p. 196068., http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12014018961/frame.html
118. Cotter, S. E., Grigsby, P. W., Siegel, B. A., Dehdashti, F., Malyapa, R. S., Fleshman, J. W., et.al. FDG-PET/CT in the evaluation of anal carcinoma, Int J Radiat Oncol Biol Phys, 2006. 65(3): p. 720-5., https://www.ncbi.nlm.nih.gov/pubmed/16626889
119. Mistrangelo, M., Pelosi, E., Bello, M., Ricardi, U., Milanesi, E., Cassoni, P., et.al. Role of positron emission tomography-computed tomography in the management of anal cancer, Int J Radiat Oncol Biol Phys, 2012. 84(1): p. 66-72., https://www.ncbi.nlm.nih.gov/pubmed/22592047
120. Pepek, J. M., Willett, C. G., Czito, B. G., Radiation therapy advances for treatment of anal cancer, J Natl Compr Canc Netw, 2010. 8(1): p. 123-9., https://www.ncbi.nlm.nih.gov/pubmed/20064294
121. Trautmann, T. G., Zuger, J. H., Positron Emission Tomography for pretreatment staging and posttreatment evaluation in cancer of the anal canal, Mol Imaging Biol, 2005. 7(4): p. 309-13., https://www.ncbi.nlm.nih.gov/pubmed/16028002
122. Jones, M., Hruby, G., Solomon, M., Rutherford, N., Martin, J., The Role of FDG-PET in the Initial Staging and Response Assessment of Anal Cancer: A Systematic Review and Meta-analysis, Ann Surg Oncol, 2015. 22(11): p. 3574-81., https://www.ncbi.nlm.nih.gov/pubmed/25652048
123. Sabbagh, A., Jacobs, C., Cooke, R., Chu, K. Y., Ng, S. M., Strauss, V. Y., et.al. Is There a Role for an 18F-fluorodeoxyglucose-derived Biological Boost in Squamous Cell Anal Cancer?, Clin Oncol (R Coll Radiol), 2019. 31(2): p. 72-80., https://www.ncbi.nlm.nih.gov/pubmed/30583927
124. Rusten, E., Rekstad, B. L., Undseth, C., Al-Haidari, G., Hanekamp, B., Hernes, E., et.al. Target volume delineation of anal cancer based on magnetic resonance imaging or positron emission tomography, Radiat Oncol, 2017. 12(1): p. 147., https://www.ncbi.nlm.nih.gov/pubmed/28874205
125. Noorani, A., Rabey, N., Durrani, A., Walsh, Sr., Davies, Rj, Systematic review of sentinel lymph node biopsy in anal squamous cell carcinoma (Provisional abstract), International Journal of Surgery, 2013. 11(9): p. 762-766., https://pubmed.ncbi.nlm.nih.gov/23872032/
126. Tehranian, S., Treglia, G., Krag, Dn, Dabbagh, Kakhki Vr, Zakavi, Sr., Sadeghi, R., et.al. Sentinel node mapping in anal canal cancer: systematic review and meta-analysis (Provisional abstract), Journal of Gastrointestinal and Liver Diseases, 2013. 22(3): p. 321-328., http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12013058623/frame.html
127. Hagemans, J. A. W., Blinde, S. E., Nuyttens, J. J., Morshuis, W. G., Mureau, M. A. M., Rothbarth, J., et.al. Salvage Abdominoperineal Resection for Squamous Cell Anal Cancer: A 30-Year Single-Institution Experience, Ann Surg Oncol, 2018. 25(7): p. 1970-1979., https://www.ncbi.nlm.nih.gov/pubmed/29691737
128. Tanum, G., Tveit, K., Karlsen, K. O., Hauer-Jensen, M., Chemotherapy and radiation therapy for anal carcinoma. Survival and late morbidity, Cancer, 1991. 67(10): p. 2462-6., https://www.ncbi.nlm.nih.gov/pubmed/2015547
129. Epidermoid anal cancer: results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycin. UKCCCR Anal Cancer Trial Working Party. UK Co-ordinating Committee on Cancer Research, Lancet, 1996. 348(9034): p. 1049-54., https://www.ncbi.nlm.nih.gov/pubmed/8874455
130. Pawlik, T. M., Gleisner, A. L., Bauer, T. W., Adams, R. B., Reddy, S. K., Clary, B. M., et.al. Liver-directed surgery for metastatic squamous cell carcinoma to the liver: results of a multi-center analysis, Ann Surg Oncol, 2007. 14(10): p. 2807-16., https://www.ncbi.nlm.nih.gov/pubmed/17551795
131. Abdel-Nabi, H., Doerr, R. J., Lamonica, D. M., Cronin, V. R., Galantowicz, P. J., Carbone, G. M., et.al. Staging of primary colorectal carcinomas with fluorine-18 fluorodeoxyglucose whole-body PET: correlation with histopathologic and CT findings, Radiology, 1998. 206(3): p. 755-60., https://www.ncbi.nlm.nih.gov/pubmed/9494497
132. Llamas-Elvira, J. M., Rodriguez-Fernandez, A., Gutierrez-Sainz, J., Gomez-Rio, M., Bellon-Guardia, M., Ramos-Font, C., et.al. Fluorine-18 fluorodeoxyglucose PET in the preoperative staging of colorectal cancer, Eur J Nucl Med Mol Imaging, 2007. 34(6): p. 859-67., https://www.ncbi.nlm.nih.gov/pubmed/17195075
133. Akiyoshi, T., Oya, M., Fujimoto, Y., Kuroyanagi, H., Ueno, M., Yamaguchi, T., et.al. Comparison of preoperative whole-body positron emission tomography with MDCT in patients with primary colorectal cancer, Colorectal Dis, 2009. 11(5): p. 464-9., https://www.ncbi.nlm.nih.gov/pubmed/18637927
134. Furukawa, H., Ikuma, H., Seki, A., Yokoe, K., Yuen, S., Aramaki, T., et.al. Positron emission tomography scanning is not superior to whole body multidetector helical computed tomography in the preoperative staging of colorectal cancer, Gut, 2006. 55(7): p. 1007-11., https://www.ncbi.nlm.nih.gov/pubmed/16361308
135. Kam, M. H., Wong, D. C., Siu, S., Stevenson, A. R., Lai, J., Phillips, G. E., Comparison of magnetic resonance imaging-fluorodeoxy- glucose positron emission tomography fusion with pathological staging in rectal cancer, Br J Surg, 2010. 97(2): p. 266-8., https://www.ncbi.nlm.nih.gov/pubmed/20035542
136. Secretariat, H. I. V. in Europe, HIV Indicator Conditions: Guidance for Implementing HIV Testing in Adults in Health Care Settings, 2014., https://eurotest.org/media/vu5ic2ag/chip_guidance-in-short_uk_updated-jun2016_mlj.pdf
137. Mai, S. K., Welzel, G., Haegele, V., Wenz, F., The influence of smoking and other risk factors on the outcome after radiochemotherapy for anal cancer, Radiat Oncol, 2007. 2: p. 30., https://www.ncbi.nlm.nih.gov/pubmed/17711570
138. Chin-Hong, P. V., Reid, G. E., Practice, A. S. T. Infectious Diseases Community of, Human papillomavirus infection in solid organ transplant recipients: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice, Clin Transplant, 2019. 33(9): p. e13590., https://www.ncbi.nlm.nih.gov/pubmed/31077438
139. Seo, Y., Kinsella, M. T., Reynolds, H. L., Chipman, G., Remick, S. C., Kinsella, T. J., Outcomes of chemoradiotherapy with 5-Fluorouracil and mitomycin C for anal cancer in immunocompetent versus immunodeficient patients, Int J Radiat Oncol Biol Phys, 2009. 75(1): p. 143-9., https://www.ncbi.nlm.nih.gov/pubmed/19203845
140. Arbyn, M., Xu, L., Simoens, C., Martin-Hirsch, P. P., Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors, Cochrane Database Syst Rev, 2018. 5: p. CD009069., https://www.ncbi.nlm.nih.gov/pubmed/29740819
141. Giuliano, A. R., Palefsky, J. M., Goldstone, S., Moreira, E. D., Jr., Penny, M. E., Aranda, C., et.al. Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males, N Engl J Med, 2011. 364(5): p. 401-11., https://www.ncbi.nlm.nih.gov/pubmed/21288094
142. Harder, T., Wichmann, O., Klug, S. J., van der Sande, M. A. B., Wiese-Posselt, M., Efficacy, effectiveness and safety of vaccination against human papillomavirus in males: a systematic review, BMC Med, 2018. 16(1): p. 110., https://www.ncbi.nlm.nih.gov/pubmed/30016957
143. Coskuner, E. R., Ozkan, T. A., Karakose, A., Dillioglugil, O., Cevik, I., Impact of the quadrivalent HPV vaccine on disease recurrence in men exposed to HPV Infection: a randomized study, J Sex Med, 2014. 11(11): p. 2785-91., https://www.ncbi.nlm.nih.gov/pubmed/25124237
144. Hildesheim, A., Gonzalez, P., Kreimer, A. R., Wacholder, S., Schussler, J., Rodriguez, A. C., et.al. Impact of human papillomavirus (HPV) 16 and 18 vaccination on prevalent infections and rates of cervical lesions after excisional treatment, Am J Obstet Gynecol, 2016. 215(2): p. 212 e1-212 e15., https://www.ncbi.nlm.nih.gov/pubmed/26892991
145. Wilkin, T. J., Chen, H., Cespedes, M. S., Leon-Cruz, J. T., Godfrey, C., Chiao, E. Y., et.al. A Randomized, Placebo-Controlled Trial of the Quadrivalent Human Papillomavirus Vaccine in Human Immunodeficiency Virus-Infected Adults Aged 27 Years or Older: AIDS Clinical Trials Group Protocol A5298, Clin Infect Dis, 2018. 67(9): p. 1339-1346., https://www.ncbi.nlm.nih.gov/pubmed/29659751
146. Schiller, J., Lowy, D., Explanations for the high potency of HPV prophylactic vaccines, Vaccine, 2018. 36(32 Pt A): p. 4768-4773., https://www.ncbi.nlm.nih.gov/pubmed/29325819
147. GlaxoSmithKline Gmb, H., Co, K. G., Fachinformation Cervarix, 2019.
148. Msd, Sharp, GmbH, Dohme, Fachinformation GARDASIL(R) 9, 2019.
149. Cooper, R., Mason, M., Finan, P., Byrne, P., Sebag-Montefiore, D., Defunctioning stomas prior to chemoradiation for anal cancer are usually permanent, Colorectal Dis, 2012. 14(1): p. 87-91., https://www.ncbi.nlm.nih.gov/pubmed/21114753
150. Glynne-Jones, R., Kadalayil, L., Meadows, H. M., Cunningham, D., Samuel, L., Geh, J. I., et.al. Tumour- and treatment-related colostomy rates following mitomycin C or cisplatin chemoradiation with or without maintenance chemotherapy in squamous cell carcinoma of the anus in the ACT II trial, Annals of Oncology, 2014. 25(8): p. 1616-1622., https://pubmed.ncbi.nlm.nih.gov/24827136/
151. Sunesen, K. G., Norgaard, M., Lundby, L., Havsteen, H., Buntzen, S., Thorlacius-Ussing, O., et.al. Cause-specific colostomy rates after radiotherapy for anal cancer: a Danish multicentre cohort study, J Clin Oncol, 2011. 29(26): p. 3535-40., https://www.ncbi.nlm.nih.gov/pubmed/21825256
152. Poynter, L., Lawes, D., Wegstapel, H., Summers, J., P-134 The prevalence and fate of the defunctioning stoma in anal cancer, Annals of Oncology, 2015. 26(S4): p. iv38.
153. Societies, Awmf Association of Scientific Medical, Society, D. K. G. German Cancer, S3-Leitlinie Kolorektales Karzinom (Leitlinienprogramm Onkologie der AWMF, DKG und DKH), 2019., https://www.awmf.org/uploads/tx_szleitlinien/021-007OLl_S3_Kolorektales-Karzinom-KRK_2019-01.pdf
154. Bass, E. M., Del Pino, A., Tan, A., Pearl, R. K., Orsay, C. P., Abcarian, H., Does preoperative stoma marking and education by the enterostomal therapist affect outcome?, Dis Colon Rectum, 1997. 40(4): p. 440-2.
155. Millan, M., Tegido, M., Biondo, S., García-Granero, E., Preoperative stoma siting and education by stomatherapists of colorectal cancer patients: a descriptive study in twelve Spanish colorectal surgical units, Colorectal Dis, 2010. 12(7 Online): p. e88-92.
156. Person, B., Ifargan, R., Lachter, J., Duek, S. D., Kluger, Y., Assalia, A., The impact of preoperative stoma site marking on the incidence of complications, quality of life, and patient's independence, Dis Colon Rectum, 2012. 55(7): p. 783-7.
157. Pan, Y. B., Maeda, Y., Wilson, A., Glynne-Jones, R., Vaizey, C. J., Late gastrointestinal toxicity after radiotherapy for anal cancer: a systematic literature review, Acta Oncol, 2018. 57(11): p. 1427-1437., https://www.ncbi.nlm.nih.gov/pubmed/30264638
158. Societies, Awmf Association of Scientific Medical, Supportive Therapie bei onkologischen PatientInnen, 2017.
159. Leitlinienprogramm, Onkologie, S3-Leitlinie Palliativmedizin für Patienten mit einer nicht heilbaren Krebserkrankung, Langversion 2.1 - Januar 2020, AWMF-Registernummer: 128/001OL, 2020., https://www.awmf.org/leitlinien/detail/ll/128-001OL.html
160. Leitlinienprogramm, Onkologie, S3-Leitlinie Psychoonkologische Diagnostik, Beratung und Behandlung von erwachsenen Krebspatienten, Version 1.1 – Januar 2014, AWMF-Registernummer: 032/051OL, 2014., https://www.awmf.org/uploads/tx_szleitlinien/032-051OLl_S3_Psychoonkologische_Beratung_Behandlung_2014-01_abgelaufen.pdf
161. Institute of Medicine Committee on Psychosocial Services to Cancer Patients/Families in a Community, Setting, The National Academies Collection: Reports funded by National Institutes of Health, in Cancer Care for the Whole Patient: Meeting Psychosocial Health Needs, Adler, N. E. and Page, A. E. K., Editors. 2008, National Academies Press (US), National Academy of Sciences.: Washington (DC)., https://www.ncbi.nlm.nih.gov/pubmed/20669419
162. Kusch, M., Labouvie, H., Hein-Nau, B., Schwarzkamp, U., Wolf, J., Hallek, M., [Integrated psychooncology: implementation of psychooncological health care at the Center for Integrated Oncology Cologne - Bonn], Dtsch Med Wochenschr, 2014. 139(46): p. 2357-60., https://www.ncbi.nlm.nih.gov/pubmed/25369048
163. Mortensen, G. L., Lundby, L., Patients use normalisation techniques to cope with the quality-of-life effects of anal cancer, Dan Med J, 2015. 62(3):, https://www.ncbi.nlm.nih.gov/pubmed/25748862
164. Sodergren, S. C., Vassiliou, V., Dennis, K., Tomaszewski, K. A., Gilbert, A., Glynne-Jones, R., et.al. Systematic review of the quality of life issues associated with anal cancer and its treatment with radiochemotherapy, Support Care Cancer, 2015. 23(12): p. 3613-23., https://www.ncbi.nlm.nih.gov/pubmed/26289529
165. Chakrabarti, S., Jin, Z., Huffman, B. M., Yadav, S., Graham, R. P., Lam-Himlin, D. M., et.al. Local excision for patients with stage I anal canal squamous cell carcinoma can be curative, J Gastrointest Oncol, 2019. 10(2): p. 171-178., https://www.ncbi.nlm.nih.gov/pubmed/31032082
166. Jelinek, S. K., Patil, N., Gaisa, M. M., Goldstone, S. E., Anal superfi cially invasive squamous cell carcinoma (SISCCA) treatments and outcomes, Sexual Health, 2015. 12 (1): p. 82., https://www.researchgate.net/publication/286779157_Anal_superficially_invasive_squamous_cell_carcinoma_SISCCA_treatments_and_outcomes
167. Greenall, M. J., Quan, S. H., Stearns, M. W., Urmacher, C., DeCosse, J. J., Epidermoid cancer of the anal margin. Pathologic features, treatment, and clinical results, Am J Surg, 1985. 149(1): p. 95-101., https://www.ncbi.nlm.nih.gov/pubmed/3966647
168. Kuss, O., Blettner, M., Borgermann, J., Propensity Score: an Alternative Method of Analyzing Treatment Effects, Dtsch Arztebl Int, 2016. 113(35-36): p. 597-603., https://www.ncbi.nlm.nih.gov/pubmed/27658473
169. Hatfield, P., Cooper, R., Sebag-Montefiore, D., Involved-field, low-dose chemoradiotherapy for early-stage anal carcinoma, Int J Radiat Oncol Biol Phys, 2008. 70(2): p. 419-24., https://www.ncbi.nlm.nih.gov/pubmed/17919842
170. Northover, J., Glynne-Jones, R., Sebag-Montefiore, D., James, R., Meadows, H., Wan, S., et.al. Chemoradiation for the treatment of epidermoid anal cancer: 13-year follow-up of the first randomised UKCCCR Anal Cancer Trial (ACT I), Br J Cancer, 2010. 102(7): p. 1123-8., https://www.ncbi.nlm.nih.gov/pubmed/20354531
171. Buckstein, M., Arens, Y., Wisnivesky, J., Gaisa, M., Goldstone, S., Sigel, K., A Population-Based Cohort Analysis of Chemoradiation Versus Radiation Alone for Definitive Treatment of Stage I Anal Cancer in Older Patients, Dis Colon Rectum, 2018. 61(7): p. 787-794., https://www.ncbi.nlm.nih.gov/pubmed/29771796
172. De Bari, B., Lestrade, L., Pommier, P., Maddalo, M., Buglione, M., Magrini, S. M., et.al. Could concomitant radio-chemotherapy improve the outcomes of early-stage node negative anal canal cancer patients? A retrospective analysis of 122 patients, Cancer Investigation, 2015. 33(4): p. 114-20.
173. Zilli, T., Schick, U., Ozsahin, M., Gervaz, P., Roth, A. D., Allal, A. S., Node-negative T1-T2 anal cancer: radiotherapy alone or concomitant chemoradiotherapy?, Radiother Oncol, 2012. 102(1): p. 62-7., https://www.ncbi.nlm.nih.gov/pubmed/21993403
174. Flam, M., John, M., Pajak, T. F., Petrelli, N., Myerson, R., Doggett, S., et.al. Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: results of a phase III randomized intergroup study, J Clin Oncol, 1996. 14(9): p. 2527-39., https://www.ncbi.nlm.nih.gov/pubmed/8823332
175. Gerard, J. P., Romestaing, P., Mornex, F., Ardiet, J. M., Radiochemotherapy in anal canal carcinoma (ACC). A randomized clinical trial comparing FluoroUracil-Cispaltinum (5FU-CDDP) and CDDP alone, European journal of cancer, 1999. 35(Suppl 4): p. S143., https://www.academia.edu/26241785/Radiochemotherapy_in_anal_canal_carcinoma_ACC_A_randomized_clinical_trial_comparing_FluoroUracil_Cisplatinum_5FU_CDDP_and_CDDP_alone
176. Ajani, J. A., Winter, K. A., Gunderson, L. L., Pedersen, J., Benson, A. B., 3rd, Thomas, C. R., Jr., et.al. Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial, JAMA, 2008. 299(16): p. 1914-21., https://www.ncbi.nlm.nih.gov/pubmed/18430910
177. Gunderson, L. L., Winter, K. A., Ajani, J. A., Pedersen, J. E., Moughan, J., Benson, A. B., 3rd, et.al. Long-term update of US GI intergroup RTOG 98-11 phase III trial for anal carcinoma: survival, relapse, and colostomy failure with concurrent chemoradiation involving fluorouracil/mitomycin versus fluorouracil/cisplatin, J Clin Oncol, 2012. 30(35): p. 4344-51., https://www.ncbi.nlm.nih.gov/pubmed/23150707
178. James, Roger D., Glynne-Jones, Robert, Meadows, Helen M., Cunningham, David, Myint, Arthur Sun, Saunders, Mark P., et.al. Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2×2 factorial trial, The Lancet Oncology, 2013. 14(6): p. 516-524., https://pubmed.ncbi.nlm.nih.gov/23578724/
179. Matzinger, O., Roelofsen, F., Mineur, L., Koswig, S., Van Der Steen-Banasik, E. M., Van Houtte, P., et.al. Mitomycin C with continuous fluorouracil or with cisplatin in combination with radiotherapy for locally advanced anal cancer (European Organisation for Research and Treatment of Cancer phase II study 22011-40014), Eur J Cancer, 2009. 45(16): p. 2782-91., https://www.ncbi.nlm.nih.gov/pubmed/19643599
180. Goodman, K. A., Julie, D., Cercek, A., Cambridge, L., Woo, K. M., Zhang, Z., et.al. Capecitabine With Mitomycin Reduces Acute Hematologic Toxicity and Treatment Delays in Patients Undergoing Definitive Chemoradiation Using Intensity Modulated Radiation Therapy for Anal Cancer, International Journal of Radiation Oncology, Biology, Physics, 2017. 98(5): p. 1087-1095.
181. Jones, C. M., Adams, R., Downing, A., Glynne-Jones, R., Harrison, M., Hawkins, M., et.al. Toxicity, Tolerability, and Compliance of Concurrent Capecitabine or 5-Fluorouracil in Radical Management of Anal Cancer With Single-dose Mitomycin-C and Intensity Modulated Radiation Therapy: Evaluation of a National Cohort, Int J Radiat Oncol Biol Phys, 2018. 101(5): p. 1202-1211., https://www.ncbi.nlm.nih.gov/pubmed/29859793
182. Meulendijks, D., Dewit, L., Tomasoa, N. B., van Tinteren, H., Beijnen, J. H., Schellens, J. H., et.al. Chemoradiotherapy with capecitabine for locally advanced anal carcinoma: an alternative treatment option, Br J Cancer, 2014. 111(9): p. 1726-33., https://www.ncbi.nlm.nih.gov/pubmed/25167226
183. Peixoto, R. D., Wan, D. D., Schellenberg, D., Lim, H. J., A comparison between 5-fluorouracil/mitomycin and capecitabine/mitomycin in combination with radiation for anal cancer, J Gastrointest Oncol, 2016. 7(4): p. 665-72., https://www.ncbi.nlm.nih.gov/pubmed/27563458
184. White, E. C., Goldman, K., Aleshin, A., Lien, W. W., Rao, A. R., Chemoradiotherapy for squamous cell carcinoma of the anal canal: Comparison of one versus two cycles mitomycin-C, Radiother Oncol, 2015. 117(2): p. 240-5., https://www.ncbi.nlm.nih.gov/pubmed/26347494
185. Yeung, R., McConnell, Y., Roxin, G., Banerjee, R., Urgoiti, G. B., MacLean, A. R., et.al. One compared with two cycles of mitomycin C in chemoradiotherapy for anal cancer: analysis of outcomes and toxicity, Curr Oncol, 2014. 21(3): p. e449-56., https://www.ncbi.nlm.nih.gov/pubmed/24940105
186. Peiffert, D., Tournier-Rangeard, L., Gerard, J. P., Lemanski, C., Francois, E., Giovannini, M., et.al. Induction chemotherapy and dose intensification of the radiation boost in locally advanced anal canal carcinoma: final analysis of the randomized UNICANCER ACCORD 03 trial, J Clin Oncol, 2012. 30(16): p. 1941-8., https://www.ncbi.nlm.nih.gov/pubmed/22529257
187. Peiffert, D., Tournier-Rangeard, L., Gerard, J. P., Lemanski, C., Francois, E., Giovannini, M., et.al. Induction chemotherapy and dose intensification of the radiation boost in locally advanced anal canal carcinoma: final analysis of the randomized UNICANCER ACCORD 03 trial, J Clin Oncol, 2012. 30(16): p. 1941-8., https://www.ncbi.nlm.nih.gov/pubmed/22529257
188. Prasad, R. N., Elson, J., Kharofa, J., The effect of dose escalation for large squamous cell carcinomas of the anal canal, Clin Transl Oncol, 2018. 20(10): p. 1314-1320., https://www.ncbi.nlm.nih.gov/pubmed/29623585
189. Bryant, A. K., Huynh-Le, M. P., Simpson, D. R., Mell, L. K., Gupta, S., Murphy, J. D., Intensity Modulated Radiation Therapy Versus Conventional Radiation for Anal Cancer in the Veterans Affairs System, Int J Radiat Oncol Biol Phys, 2018. 102(1): p. 109-115., https://www.ncbi.nlm.nih.gov/pubmed/30102186
190. Chuong, M. D., Freilich, J. M., Hoffe, S. E., Fulp, W., Weber, J. M., Almhanna, K., et.al. Intensity-Modulated Radiation Therapy vs. 3D Conformal Radiation Therapy for Squamous Cell Carcinoma of the Anal Canal, Gastrointest Cancer Res, 2013. 6(2): p. 39-45., https://www.ncbi.nlm.nih.gov/pubmed/23745158
191. Elson, J. K., Kachnic, L. A., Kharofa, J. R., Intensity-modulated radiotherapy improves survival and reduces treatment time in squamous cell carcinoma of the anus: A National Cancer Data Base study, Cancer, 2018. 124(22): p. 4383-4392., https://www.ncbi.nlm.nih.gov/pubmed/30329160
192. Koerber, S. A., Seither, B., Slynko, A., Haefner, M. F., Krug, D., Liermann, J., et.al. Chemoradiation in female patients with anal cancer: Patient-reported outcome of acute and chronic side effects, Tumori, 2019. 105(2): p. 174-180., https://www.ncbi.nlm.nih.gov/pubmed/30484384
193. Koerber, S. A., Slynko, A., Haefner, M. F., Krug, D., Schoneweg, C., Kessel, K., et.al. Efficacy and toxicity of chemoradiation in patients with anal cancer--a retrospective analysis, Radiat Oncol, 2014. 9: p. 113., https://www.ncbi.nlm.nih.gov/pubmed/24886574
194. Pollom, E. L., Wang, G., Harris, J. P., Koong, A. C., Bendavid, E., Bhattacharya, J., et.al. The Impact of Intensity Modulated Radiation Therapy on Hospitalization Outcomes in the SEER-Medicare Population With Anal Squamous Cell Carcinoma, Int J Radiat Oncol Biol Phys, 2017. 98(1): p. 177-185., https://www.ncbi.nlm.nih.gov/pubmed/28258896
195. Rattan, R., Kapoor, R., Bahl, A., Gupta, R., Oinam, A. S., Kaur, S., Comparison of bone marrow sparing intensity modulated radiotherapy (IMRT) and three-dimensional conformal radiotherapy (3DCRT) in carcinoma of anal canal: a prospective study, Ann Transl Med, 2016. 4(4): p. 70., https://www.ncbi.nlm.nih.gov/pubmed/27004217
196. Spencer, C. R., Cardenas, M., DeWees, T. A., Jain, R., Grigsby, P., Tan, B., et.al. Outcomes after IMRT compared to 3DCRT for squamous cell carcinoma of the anus, International Journal of Radiation Oncology Biology Physics, 2014. 1): p. S400-S401., https://www.researchgate.net/publication/280279039_Outcomes_After_IMRT_Compared_to_3DCRT_for_Squamous_Cell_Carcinoma_of_the_Anus
197. Weber, H. E., Droge, L. H., Hennies, S., Herrmann, M. K., Gaedcke, J., Wolff, H. A., Volumetric intensity-modulated arc therapy vs. 3-dimensional conformal radiotherapy for primary chemoradiotherapy of anal carcinoma: Effects on treatment-related side effects and survival, Strahlenther Onkol, 2015. 191(11): p. 827-34., https://www.ncbi.nlm.nih.gov/pubmed/26050046
198. Yeung, R., McConnell, Y., Warkentin, H., Graham, D., Warkentin, B., Joseph, K., et.al. Intensity-Modulated Radiotherapy (IMRT) vs Helical Tomotherapy (HT) in Concurrent Chemoradiotherapy (CRT) for Patients with Anal Canal Carcinoma (ACC): an analysis of dose distribution and toxicities, Radiat Oncol, 2015. 10: p. 92., https://www.ncbi.nlm.nih.gov/pubmed/25903798
199. Konski, A., Garcia, M., Jr., John, M., Krieg, R., Pinover, W., Myerson, R., et.al. Evaluation of planned treatment breaks during radiation therapy for anal cancer: update of RTOG 92-08, Int J Radiat Oncol Biol Phys, 2008. 72(1): p. 114-8., https://www.ncbi.nlm.nih.gov/pubmed/18472363
200. Geltzeiler, C. B., Nabavizadeh, N., Kim, J., Lu, K. C., Billingsley, K. G., Thomas, C. R., et.al. Chemoradiotherapy with a radiation boost for anal cancer decreases the risk for salvage abdominoperineal resection: analysis from the national cancer data base, Ann Surg Oncol, 2014. 21(11): p. 3616-20., https://www.ncbi.nlm.nih.gov/pubmed/24943237
201. Budde, C. N., Nabavizadeh, N., Kim, J., Lu, K. C., Billingsley, K. G., Thomas, C. R., et.al. Boost radiation treatment for anal cancer decreases the risk for lifetime colostomy: Analysis from the national cancer data base (NCDB), Annals of Surgical Oncology, 2014. 1): p. S76., https://www.researchgate.net/publication/296048211_Boost_Radiation_Treatment_for_Anal_Cancer_Decreases_the_Risk_for_Lifetime_Colostomy_Analysis_from_the_National_Cancer_Data_Base_NCDB#fullTextFileContent
202. Franco, P., De Bari, B., Arcadipane, F., Lepinoy, A., Ceccarelli, M., Furfaro, G., et.al. Comparing simultaneous integrated boost vs sequential boost in anal cancer patients: results of a retrospective observational study, Radiat Oncol, 2018. 13(1): p. 172., https://www.ncbi.nlm.nih.gov/pubmed/30201015
203. Althaqfi, S., Goel, R., Chandni, J., Biotech, Y. X. M., Grimard, L., Results of brachytherapy in anal cancer from a cohort of 173 patients treated at the same institution over a 20 year period, European Journal of Cancer, 2015. 3): p. S126., https://www.ejcancer.com/article/S0959-8049(16)30367-7/fulltext
204. Hannoun-Levi, J. M., Ortholan, C., Resbeut, M., Teissier, E., Ronchin, P., Cowen, D., et.al. High-dose split-course radiation therapy for anal cancer: outcome analysis regarding the boost strategy (CORS-03 study), International Journal of Radiation Oncology, Biology, Physics, 2011. 80(3): p. 712-20., https://pubmed.ncbi.nlm.nih.gov/20619552/
205. Oehler-Janne, C., Seifert, B., Lutolf, U. M., Studer, G., Glanzmann, C., Ciernik, I. F., Clinical outcome after treatment with a brachytherapy boost versus external beam boost for anal carcinoma, Brachytherapy, 2007. 6(3): p. 218-26., https://www.ncbi.nlm.nih.gov/pubmed/17681244
206. Arcelli, A., Buwenge, M., Macchia, G., Cammelli, S., Deodato, F., Cilla, S., et.al. Long-term results of chemoradiation plus pulsed-dose-rate brachytherapy boost in anal canal carcinoma: A mono-institutional retrospective analysis, J Contemp Brachytherapy, 2019. 11(1): p. 21-27., https://www.ncbi.nlm.nih.gov/pubmed/30911306
207. Moureau-Zabotto, L., Ortholan, C., Hannoun-Levi, J. M., Teissier, E., Cowen, D., Salem, N., et.al. Role of brachytherapy in the boost management of anal carcinoma with node involvement (CORS-03 study), Int J Radiat Oncol Biol Phys, 2013. 85(3): p. e135-42., https://www.ncbi.nlm.nih.gov/pubmed/23195780
208. Kouloulias, V., Plataniotis, G., Kouvaris, J., Dardoufas, C., Gennatas, C., Uzunoglu, N., et.al. Chemoradiotherapy combined with intracavitary hyperthermia for anal cancer: feasibility and long-term results from a phase II randomized trial, Am J Clin Oncol, 2005. 28(1): p. 91-9., https://www.ncbi.nlm.nih.gov/pubmed/15685041
209. Ott, O. J., Schmidt, M., Semrau, S., Strnad, V., Matzel, K. E., Schneider, I., et.al. Chemoradiotherapy with and without deep regional hyperthermia for squamous cell carcinoma of the anus, Strahlenther Onkol, 2019. 195(7): p. 607-614., https://www.ncbi.nlm.nih.gov/pubmed/30390114
210. Bruggmoser, G., Bauchowitz, S., Canters, R., Crezee, H., Ehmann, M., Gellermann, J., et.al. Guideline for the clinical application, documentation and analysis of clinical studies for regional deep hyperthermia: quality management in regional deep hyperthermia, Strahlenther Onkol, 2012. 188 Suppl 2: p. 198-211., https://www.ncbi.nlm.nih.gov/pubmed/22926657
211. Chapet, O., Gerard, J. P., Riche, B., Alessio, A., Mornex, F., Romestaing, P., Prognostic value of tumor regression evaluated after first course of radiotherapy for anal canal cancer, Int J Radiat Oncol Biol Phys, 2005. 63(5): p. 1316-24., https://www.ncbi.nlm.nih.gov/pubmed/16169674
212. Scricciolo, M., Mantello, G., Cucciarelli, F., Vicenzi, L., Fabbietti, L., Fenu, F., et.al. Optimum time to assess complete response following radiochemotherapy in anal canal cancer patients, Radiotherapy and Oncology, 2015. 1): p. S658., https://www.researchgate.net/publication/282537557_EP-1215_Optimum_time_to_assess_complete_response_following_radiochemotherapy_in_anal_canal_cancer_patients
213. Lee, G. C., Ricciardi, R., Stafford, C., Francone, T. D., Bordeianou, L., Kunitake, H., Waiting >3 months between radiation and salvage APR is associated with positive margins in patients with anal cancer treated with concurrent chemoradiation, Diseases of the Colon and Rectum, 2019. 62(6): p. e286.
214. Houard, C., Pinaquy, J. B., Mesguich, C., Henriques de Figueiredo, B., Cazeau, A. L., Allard, J. B., et.al. Role of (18)F-FDG PET/CT in Posttreatment Evaluation of Anal Carcinoma, J Nucl Med, 2017. 58(9): p. 1414-1420., https://www.ncbi.nlm.nih.gov/pubmed/28280225
215. Teagle, A. R., Gilbert, D. C., Jones, J. R., Burkill, G. J., McKinna, F., Dizdarevic, S., Negative 18F-FDG-PET-CT may exclude residual or recurrent disease in anal cancer, Nucl Med Commun, 2016. 37(10): p. 1038-45., https://www.ncbi.nlm.nih.gov/pubmed/27341410
216. Kochhar, Rohit, Renehan, Andrew G., Mullan, Damian, Chakrabarty, Bipasha, Saunders, Mark P., Carrington, Bernadette M., The assessment of local response using magnetic resonance imaging at 3- and 6-month post chemoradiotherapy in patients with anal cancer, European Radiology, 2016. 27(2): p. 607-617., https://pubmed.ncbi.nlm.nih.gov/27090113/
217. National Cancer, Institute, Surveillance, Epidemiology, End Results, Program, Cancer Stat Facts: Anal Cancer, 2019., https://seer.cancer.gov/statfacts/html/anus.html
218. Abunassar, M., Reinders, J., Jonker, D. J., Asmis, T., Review of anal cancer patients at the Ottawa hospital, Eur J Surg Oncol, 2015. 41(5): p. 653-8., https://www.ncbi.nlm.nih.gov/pubmed/25776438
219. Ferenschild, F. T., Vermaas, M., Hofer, S. O., Verhoef, C., Eggermont, A. M., de Wilt, J. H., Salvage abdominoperineal resection and perineal wound healing in local recurrent or persistent anal cancer, World J Surg, 2005. 29(11): p. 1452-7., https://www.ncbi.nlm.nih.gov/pubmed/16222445
220. Mullen, J. T., Rodriguez-Bigas, M. A., Chang, G. J., Barcenas, C. H., Crane, C. H., Skibber, J. M., et.al. Results of surgical salvage after failed chemoradiation therapy for epidermoid carcinoma of the anal canal, Ann Surg Oncol, 2007. 14(2): p. 478-83., https://www.ncbi.nlm.nih.gov/pubmed/17103253
221. Papaconstantinou, H. T., Bullard, K. M., Rothenberger, D. A., Madoff, R. D., Salvage abdominoperineal resection after failed Nigro protocol: modest success, major morbidity, Colorectal Dis, 2006. 8(2): p. 124-9., https://www.ncbi.nlm.nih.gov/pubmed/16412072
222. Roohipour, R., Patil, S., Goodman, K. A., Minsky, B. D., Wong, W. D., Guillem, J. G., et.al. Squamous-cell carcinoma of the anal canal: predictors of treatment outcome, Dis Colon Rectum, 2008. 51(2): p. 147-53., https://www.ncbi.nlm.nih.gov/pubmed/18180997
223. Stewart, D., Yan, Y., Kodner, I. J., Birnbaum, E., Fleshman, J., Myerson, R., et.al. Salvage surgery after failed chemoradiation for anal canal cancer: should the paradigm be changed for high-risk tumors?, J Gastrointest Surg, 2007. 11(12): p. 1744-51., https://link.springer.com/content/pdf/10.1007%2Fs11605-007-0232-x.pdf
224. Ko, G., Sarkaria, A., Merchant, S. J., Booth, C. M., Patel, S. V., A systematic review of outcomes after salvage abdominoperineal resection for persistent or recurrent anal squamous cell cancer, Colorectal Dis, 2019. 21(6): p. 632-650., https://www.ncbi.nlm.nih.gov/pubmed/30689272
225. Fraunholz, I., Weiss, C., Eberlein, K., Haberl, A., Rodel, C., Concurrent chemoradiotherapy with 5-fluorouracil and mitomycin C for invasive anal carcinoma in human immunodeficiency virus-positive patients receiving highly active antiretroviral therapy, Int J Radiat Oncol Biol Phys, 2010. 76(5): p. 1425-32., https://www.ncbi.nlm.nih.gov/pubmed/19744801
226. Nyitray, A. G., Hicks, J. T., Hwang, L. Y., Baraniuk, S., White, M., Millas, S., et.al. A phase II clinical study to assess the feasibility of self and partner anal examinations to detect anal canal abnormalities including anal cancer, Sex Transm Infect, 2018. 94(2): p. 124-130., https://www.ncbi.nlm.nih.gov/pubmed/28835533
227. Duimering, A., Riauka, T., Nijjar, Y., Ghosh, S., MacEwan, R., Warkentin, H., et.al. Prognostic utility of pre- and post-treatment FDG-PET parameters in anal squamous cell carcinoma, Radiother Oncol, 2019. 136: p. 21-28., https://www.ncbi.nlm.nih.gov/pubmed/31015125
228. Jones, M. P., Hruby, G., Metser, U., Sridharan, S., Capp, A., Kumar, M., et.al. FDG-PET parameters predict for recurrence in anal cancer - results from a prospective, multicentre clinical trial, Radiat Oncol, 2019. 14(1): p. 140., https://www.ncbi.nlm.nih.gov/pubmed/31387597
229. Lampejo, T., Kavanagh, D., Clark, J., Goldin, R., Osborn, M., Ziprin, P., et.al. Prognostic biomarkers in squamous cell carcinoma of the anus: a systematic review, Br J Cancer, 2010. 103(12): p. 1858-69., https://www.ncbi.nlm.nih.gov/pubmed/21063399
230. Gilbert, D. C., Wakeham, K., Langley, R. E., Vale, C. L., Increased risk of second cancers at sites associated with HPV after a prior HPV-associated malignancy, a systematic review and meta-analysis, Br J Cancer, 2019. 120(2): p. 256-268., https://www.ncbi.nlm.nih.gov/pubmed/30482913
231. Faivre, C., Rougier, P., Ducreux, M., Mitry, E., Lusinchi, A., Lasser, P., et.al. [5-fluorouracile and cisplatinum combination chemotherapy for metastatic squamous-cell anal cancer], Bull Cancer, 1999. 86(10): p. 861-5., https://www.ncbi.nlm.nih.gov/pubmed/10572237
232. Portelance, L., Kopek, N., Hosein, P., Restrepo, M., Rocha-Lima, C., Levi, J., et.al. A Multidisciplinary Approach to the Management of Patients Diagnosed With Stage IV Anal Canal Cancer: A Multi-institutional Retrospective Study, Oncology. Conference: 96th Annual Meeting of the American Radium Society, ARS, 2014. 28(1S):, https://www.cancernetwork.com/ars-2014/p099-multidisciplinary-approach-management-patients-diagnosed-stage-iv-anal-canal-cancer-multihttps://www.cancernetwork.com/ars-2014/p099-multidisciplinary-approach-management-patients-diagnosed-stage-iv-anal-canal-cancer-multi
233. Sclafani, F., Morano, F., Cunningham, D., Baratelli, C., Kalaitzaki, E., Watkins, D., et.al. Platinum-Fluoropyrimidine and Paclitaxel-Based Chemotherapy in the Treatment of Advanced Anal Cancer Patients, Oncologist, 2017. 22(4): p. 402-408., https://www.ncbi.nlm.nih.gov/pubmed/28209745
234. Tanum, G., Treatment of relapsing anal carcinoma, Acta Oncol, 1993. 32(1): p. 33-5., https://www.ncbi.nlm.nih.gov/pubmed/8466762
235. Wilking, N., Petrelli, N., Herrera, L., Mittelman, A., Phase II study of combination bleomycin, vincristine and high-dose methotrexate (BOM) with leucovorin rescue in advanced squamous cell carcinoma of the anal canal, Cancer Chemother Pharmacol, 1985. 15(3): p. 300-2., https://www.ncbi.nlm.nih.gov/pubmed/2414024
236. Kim, R., Byer, J., Fulp, W. J., Mahipal, A., Dinwoodie, W., Shibata, D., Carboplatin and paclitaxel treatment is effective in advanced anal cancer, Oncology, 2014. 87(2): p. 125-32., https://www.ncbi.nlm.nih.gov/pubmed/25012155
237. Hong, D. S., Moore, K., Patel, M., Grant, S. C., Burris, H. A., 3rd, William, W. N., Jr., et.al. Evaluation of Prexasertib, a Checkpoint Kinase 1 Inhibitor, in a Phase Ib Study of Patients with Squamous Cell Carcinoma, Clin Cancer Res, 2018. 24(14): p. 3263-3272., https://www.ncbi.nlm.nih.gov/pubmed/29643063
238. Morris, V. K., Salem, M. E., Nimeiri, H., Iqbal, S., Singh, P., Ciombor, K., et.al. Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, single-arm, phase 2 study, Lancet Oncol, 2017. 18(4): p. 446-453., https://www.ncbi.nlm.nih.gov/pubmed/28223062
239. Ott, P. A., Piha-Paul, S. A., Munster, P., Pishvaian, M. J., van Brummelen, E. M. J., Cohen, R. B., et.al. Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with recurrent carcinoma of the anal canal, Ann Oncol, 2017. 28(5): p. 1036-1041., https://www.ncbi.nlm.nih.gov/pubmed/28453692
240. Kim, D. W., Byer, J., Kothari, N., Mahipal, A., Chang, Y. D., Kim, R. D., EGFR Inhibitors in Patients with Advanced Squamous Cell Anal Carcinomas: A Single-Institution Experience, Oncology, 2017. 92(4): p. 190-196., https://www.ncbi.nlm.nih.gov/pubmed/28152526
241. Rogers, J. E., Ohinata, A., Silva, N. N., Mehdizadeh, A., Eng, C., Epidermal growth factor receptor inhibition in metastatic anal cancer, Anticancer Drugs, 2016. 27(8): p. 804-8., https://www.ncbi.nlm.nih.gov/pubmed/27272412
242. Kim, S., Francois, E., Andre, T., Samalin, E., Jary, M., El Hajbi, F., et.al. Docetaxel, cisplatin, and fluorouracil chemotherapy for metastatic or unresectable locally recurrent anal squamous cell carcinoma (Epitopes-HPV02): a multicentre, single-arm, phase 2 study, Lancet Oncol, 2018. 19(8): p. 1094-1106., https://www.ncbi.nlm.nih.gov/pubmed/30042063
243. Eng, C., Chang, G. J., You, Y. N., Das, P., Rodriguez-Bigas, M., Xing, Y., et.al. The role of systemic chemotherapy and multidisciplinary management in improving the overall survival of patients with metastatic squamous cell carcinoma of the anal canal, Oncotarget, 2014. 5(22): p. 11133-42., https://www.ncbi.nlm.nih.gov/pubmed/25373735
244. Mondaca, S., Chatila, W. K., Bates, D., Hechtman, J. F., Cercek, A., Segal, N. H., et.al. FOLFCIS Treatment and Genomic Correlates of Response in Advanced Anal Squamous Cell Cancer, Clin Colorectal Cancer, 2019. 18(1): p. e39-e52., https://www.ncbi.nlm.nih.gov/pubmed/30316684
245. Abdelazim, Y. A., Rushing, C. N., Palta, M., Willett, C. G., Czito, B. G., Role of pelvic chemoradiation therapy in patients with initially metastatic anal canal cancer: A National Cancer Database review, Cancer, 2019. 125(12): p. 2115-2122., https://www.ncbi.nlm.nih.gov/pubmed/30825391
246. Repka, M. C., Aghdam, N., Karlin, A. W., Unger, K. R., Social determinants of stage IV anal cancer and the impact of pelvic radiotherapy in the metastatic setting, Cancer Med, 2017. 6(11): p. 2497-2506., https://www.ncbi.nlm.nih.gov/pubmed/28980407
247. Wang, Y., Yu, X., Zhao, N., Wang, J., Lin, C., Izaguirre, E. W., et.al. Definitive Pelvic Radiotherapy and Survival of Patients With Newly Diagnosed Metastatic Anal Cancer, J Natl Compr Canc Netw, 2019. 17(1): p. 29-37., https://www.ncbi.nlm.nih.gov/pubmed/30659127
248. Evesque, L., Benezery, K., Follana, P., Tuan Falk, A., Doyen, J., Reure, J., et.al. Multimodal Therapy of Squamous Cell Carcinoma of the Anus With Distant Metastasis: A Single-Institution Experience, Dis Colon Rectum, 2017. 60(8): p. 785-791., https://www.ncbi.nlm.nih.gov/pubmed/28682963
249. Omichi, K., Mizuno, T., Okuno, M., Tzeng, C. D., Conrad, C., Chun, Y. S., et.al. Long term outcome after resection of liver metastases from squamous cell carcinoma, Eur J Surg Oncol, 2017. 43(11): p. 2129-2134., https://www.ncbi.nlm.nih.gov/pubmed/28958732
250. Radbruch, L., Payne, S., European Association for Palliative, Care, White Paper on standards and norms for hospice andpalliative care in Europe: part 1, European Journal of Palliative Care, 2009. 16(6): p. 278-89.
251. Alt-Epping, B., Nauck, F., Schneider, N., Leben bis zuletzt. Hausärztliche und spezialisierte Palliativversorgung bei schwerstkranken Patienten., Der Hausarzt, 2012. 11: p. 43-46.
252. Haun, M. W., Estel, S., Rucker, G., Friederich, H. C., Villalobos, M., Thomas, M., et.al. Early palliative care for adults with advanced cancer, Cochrane Database Syst Rev, 2017. 6(6): p. CD011129., https://www.ncbi.nlm.nih.gov/pubmed/28603881
253. Adler, K., Schlieper, D., Kindgen-Milles, D., Meier, S., Schwartz, J., van Caster, P., et.al. Integration der Palliativmedizin in die Intensivmedizin, Der Anaesthesist, 2017. 66(9): p. 660-666., https://doi.org/10.1007/s00101-017-0326-0
254. Dalgaard, K. M., Bergenholtz, H., Nielsen, M. E., Timm, H., Early integration of palliative care in hospitals: A systematic review on methods, barriers, and outcome, Palliat Support Care, 2014. 12(6): p. 495-513., https://www.ncbi.nlm.nih.gov/pubmed/24621947
255. Davis, M. P., Temel, J. S., Balboni, T., Glare, P., A review of the trials which examine early integration of outpatient and home palliative care for patients with serious illnesses, Ann Palliat Med, 2015. 4(3): p. 99-121., https://www.ncbi.nlm.nih.gov/pubmed/26231807
256. Gaertner, J., Siemens, W., Meerpohl, J. J., Antes, G., Meffert, C., Xander, C., et.al. Effect of specialist palliative care services on quality of life in adults with advanced incurable illness in hospital, hospice, or community settings: systematic review and meta-analysis, BMJ, 2017. 357: p. j2925., https://www.ncbi.nlm.nih.gov/pubmed/28676557
257. Hui, D., Kim, Y. J., Park, J. C., Zhang, Y., Strasser, F., Cherny, N., et.al. Integration of oncology and palliative care: a systematic review, Oncologist, 2015. 20(1): p. 77-83., https://www.ncbi.nlm.nih.gov/pubmed/25480826
258. Hui, D., Meng, Y. C., Bruera, S., Geng, Y., Hutchins, R., Mori, M., et.al. Referral Criteria for Outpatient Palliative Cancer Care: A Systematic Review, Oncologist, 2016. 21(7): p. 895-901., https://www.ncbi.nlm.nih.gov/pubmed/27185614
259. Tassinari, D., Drudi, F., Monterubbianesi, M. C., Stocchi, L., Ferioli, I., Marzaloni, A., et.al. Early Palliative Care in Advanced Oncologic and Non-Oncologic Chronic Diseases: A Systematic Review of Literature, Rev Recent Clin Trials, 2016. 11(1): p. 63-71., https://www.ncbi.nlm.nih.gov/pubmed/26464077
260. Ferrell, B. R., Temel, J. S., Temin, S., Alesi, E. R., Balboni, T. A., Basch, E. M., et.al. Integration of Palliative Care Into Standard Oncology Care: American Society of Clinical Oncology Clinical Practice Guideline Update, J Clin Oncol, 2017. 35(1): p. 96-112., https://www.ncbi.nlm.nih.gov/pubmed/28034065
261. Dgppn, BÄK K. B. V. Awmf für die Leitliniengruppe Unipolare Depression, S3-Leitlinie/Nationale VersorgungsLeitlinie Unipolare Depression - Langfassung, 2. Auflage. Version 5, 2015., https://www.awmf.org/uploads/tx_szleitlinien/nvl-005l_S3_Unipolare_Depression_2017-05.pdf
262. Mittal, R., Perakath, B., Chase, S., Jesudason, M. R., Nayak, S., Transanal excision of anorectal lesions--a single centre experience, Trop Gastroenterol, 2010. 31(1): p. 65-8., https://www.ncbi.nlm.nih.gov/pubmed/20860237
263. Schlag, P., [How does quality of life modify indications for palliative surgical measures?], Langenbecks Arch Chir Suppl II Verh Dtsch Ges Chir, 1989. p. 129-35., https://www.ncbi.nlm.nih.gov/pubmed/2485148
264. Cramp, F., Byron-Daniel, J., Exercise for the management of cancer-related fatigue in adults, Cochrane Database Syst Rev, 2012. 11: p. CD006145., https://www.ncbi.nlm.nih.gov/pubmed/23152233
265. Streckmann, F., Zopf, E. M., Lehmann, H. C., May, K., Rizza, J., Zimmer, P., et.al. Exercise intervention studies in patients with peripheral neuropathy: a systematic review, Sports Med, 2014. 44(9): p. 1289-304., https://www.ncbi.nlm.nih.gov/pubmed/24927670
266. Guyatt, G., Oxman, A. D., Akl, E. A., Kunz, R., Vist, G., Brozek, J., et.al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables, J Clin Epidemiol, 2011. 64(4): p. 383-94., https://www.ncbi.nlm.nih.gov/pubmed/21195583
267. Guyatt, G. H., Oxman, A. D., Kunz, R., Atkins, D., Brozek, J., Vist, G., et.al. GRADE guidelines: 2. Framing the question and deciding on important outcomes, J Clin Epidemiol, 2011. 64(4): p. 395-400., https://www.ncbi.nlm.nih.gov/pubmed/21194891
268. Muirhead, R., Adams, R. A., Gilbert, D. C., Harrison, M., Glynne-Jones, R., Sebag-Montefiore, D., et.al. NATIONAL GUIDANCE FOR IMRT IN ANAL CANCER, Version 3. 18/04/2016, 2016., http://analimrtguidance.co.uk/national-anal-imrt-guidance-v3.pdf
269. Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaf, D.K., AWMF),, Entwicklung von leitlinienbasierten Qualitätsindikatoren. Methodenpapier für das Leitlinienprogramm Onkologie, Version 2.1., 2017., http://www.leitlinienprogrammonkologie.de/methodik/informationen-zur-methodik/